Embodiments of the present disclosure include anti-inflammatory compositions and methods of use thereof. The compositions include purified lipids from Francisella, for example, virulent strains of Francisella. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

The present invention is directed to novel polynucleotides, polypeptides, and polyproteins of Mycoplasma surface proteins, all of which are useful in detecting infection and for the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against Mycoplasma infections. Detection and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention. Assays, kits, systems, and nanoparticle encapsulated compositions related to the polynucleotides, polypeptides, polyproteins, antibodies or fragments, derivatives, and variants thereof are also disclosed.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

Methods of eliciting and/or modulating immune responses, therapeutic methods, and antigen delivery methods that include the step of administering a protein particle derived from a cell, the protein particle comprising a diphtheria toxin Cross Reacting Material (CRM) amino acid sequence are disclosed. Included are diagnostic methods using the protein particle derived from a cell, the protein particle comprising a diphtheria toxin CRM amino acid sequence. The methods disclosed herein may be useful as an antigen carrier delivery system.

The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient.

The present invention discloses application of a bile acid composite bacterial agent in the preparation of feed additives for mutton sheep. The bile acid composite bacterial agent comprises Parabacteroides distasonis bacterial suspension and bile acid, and the Parabacteroides distasonis bacterial suspension is obtained by cultivation and fermentation of Parabacteroides distasonis LCG-06 with the deposit number CGMCC No. 20820. The bile acid composite bacterial agent of the present invention has natural components and has no toxic and side effects, and can significantly increase the growth rate of mutton sheep and promote nutrition absorption, accelerate the decomposition of in vivo fat of mutton sheep, thereby reducing the body fat percentage of mutton sheep, increasing the slaughter weight and slaughter rate of mutton sheep, increasing the incomes for breeding of mutton sheep. Therefore, it has broad application prospects.